Page last updated: 2024-12-06
4,5-dihydroxy-1,2-dithiane
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 445528 |
| CHEBI ID | 41837 |
| SCHEMBL ID | 1628866 |
| MeSH ID | M0167952 |
Synonyms (30)
| Synonym |
|---|
| l-4,5-dihydroxy-1,2-dithiane |
| o-dithiane, 4,5-dihydroxy-, l- |
| 4,5(trans)-dioxide-1,2-dithiane |
| (4s,5s)-dithiane-4,5-diol |
| nsc663605 |
| CHEBI:41837 |
| DB02693 |
| d1d , |
| (4s,5s)-1,2-dithiane-4,5-diol |
| SR-01000634012-1 |
| (4s,5s)-4,5-dihydroxy-1,2-dithiane |
| D-8230 |
| trans-4,5-dihydroxy-1,2-dithian |
| trans-4,5-dihydroxy-1,2-dithiane, >=99% |
| inchi=1/c4h8o2s2/c5-3-1-7-8-2-4(3)6/h3-6h,1-2h2/t3-,4-/m1/s1 |
| ypgmowhxeqdbbv-qwwzwvqmsa- |
| 1,2-dithiane-4,5-diol,(4r,5r)-rel- |
| c4h8o2s2 |
| CCG-44158 |
| 1,2-dithiane-4,5-diol, (4s,5s)- |
| (-)-trans-1,2-dithiane-4,5-diol |
| trans-4,5-dihydroxy-1,2-dithiane(s,s) |
| 8t052md8ap , |
| 37031-12-2 |
| unii-8t052md8ap |
| SCHEMBL1628866 |
| DTXSID80190534 |
| mfcd00006661 |
| Q27104484 |
| CS-0157913 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| trans-1,2-dithiane-4,5-diol | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Pathways (1)
| Pathway | Proteins | Compounds |
|---|---|---|
| Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-2 | 0 | 490 |
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||